VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts

I. Gutiérrez-Canñas, Y. Juarranz1, B. Santiago, A. Arranz1, C. Martinez2, M. Galindo, M. Payá, R. P. Gomariz1 and J. L. Pablos

Objectives. Vasoactive intestinal peptide (VIP) has demonstrated therapeutic effects in arthritis by inhibiting both innate and acquired immune responses. We investigated the potential effects of VIP in the regulation of Toll-like receptor (TLR) expression and function in synovial fibroblasts from patients with rheumatoid arthritis (RA) and osteoarthritis (OA).

Methods. Cultured fibroblast-like synoviocytes (FLS) were obtained from patients with RA and OA. The effects of VIP on basal or TNF-α or lipopolysaccharide (LPS)-induced TLR2, TLR4 and MyD88 expression and its effects on TLR4-mediated CCL2 and CXCL8 chemokine production were studied by reverse transcription–polymerase chain reaction, western blotting and enzyme-linked immunosorbent assay.

Results. TLR2, TLR4 and MyD88 mRNA expression was increased in RA FLS as compared with OA FLS. The largest increase was observed for TLR4 and there was also overexpression at the protein level in RA FLS. TLR4 and MyD88 mRNA and proteins were induced by LPS and TNF-α in RA FLS. VIP down-regulated the induced but not the constitutive expression of TLR4 and MyD88 in RA FLS. VIP treatment decreased CCL2 and CXCL8 chemokine production in response to TLR4 activation with LPS in RA FLS.

Conclusions. We demonstrate that VIP down-regulates LPS and TNF-α activation of TLR4 expression and the TLR4 functional response in terms of proinflammatory chemokine production. These studies suggest that the pleiotropic anti-inflammatory actions of VIP involve inhibitory effects on TLR4 expression and signalling.

Key words: VIP, TLR, Rheumatoid arthritis, Osteoarthritis, Chemokines.

Vasoactive intestinal peptide (VIP) is a widely distributed neuropeptide that displays potent anti-inflammatory and immunomodulatory activity by down-regulating proinflammatory and T-cell cytokines in immune-mediated diseases [1]. A beneficial effect of VIP on experimental animal models of acute and chronic inflammation, such as acute pancreatitis [2], septic shock [3], arthritis [4], inflammatory bowel disease [5] and lipopolysaccharide (LPS)-induced acute inflammation [6], has been demonstrated. In collagen-induced arthritis, VIP showed pleiotropic effects on both the innate and acquired branches of the autoimmune inflammatory response, by limiting proinflammatory cytokines production, shifting the Th1/Th2 balance [4] and showing a protective effect on joint destruction [7]. Although these mechanisms seem involved in the development of human rheumatoid arthritis (RA), cytokines and proinflammatory networks play an unequivocal role, as confirmed by the success of cytokine-targeted therapies, whereas the role of Th1/Th2 bias is less clear [8]. In human RA synovial cells, previous studies suggest that VIP can modulate cytokine and chemokine networks, particularly in TNF-α-stimulated cells [9, 10].

Toll-like receptors (TLR) are receptors expressed on the plasma membrane or in the intracellular compartment that recognize common molecules produced by pathogens, named pathogen-associated molecular patterns (PAMPs). They are conserved proteins with an extracellular leucine-rich domain and an intracellular Toll/IL-1 like receptor (TLR) domain. To date, 11 members of the TLR family have been identified in humans, TLR4 being the first to be described [11–13]. This receptor is essential for LPS signalling; this signalling also requires an additional molecule, MD-2, which associates with the extracellular portion of TLR4. In addition, TLR4 has been involved in the recognition of endogenous ligands, such as hsp60, fibronectin and multiple host proteins [11, 14]. TLR4 can signal through the adapter protein MyD88 as well as through MyD88-independent pathways, resulting in the activation of various intracellular signalling cascades, which lead to the activation of transcription factors of the nuclear transcription factor-κB (NFκB) and interferon regulatory factor (IRF) families, which ultimately induce the production of inflammatory mediators [11–13].

Although the specific ligands involved in TLR activation during autoimmune disease are unclear, TLR signalling seems involved in the pathogenesis of autoimmune inflammatory diseases, including arthritis, as revealed by genetically deficient mouse models [15–17]. In RA, TLR ligands of microbial origin, such as peptidoglycans (PGs) and double-stranded DNA, or endogenous ligands, such as heat shock proteins, fibrinogen, and hyaluronan or necrotic cell components, are commonly found in inflamed joints and have been proposed as potential TLR ligands.
in this milieu (for review see [18]). The expression and function of TLR in RA tissues or cells have been studied by different groups. Higher expression of TLR2 and TLR4 in synovial tissues has been found in RA patients compared with patients with osteoarthritis (OA) and healthy individuals [19]. However, previous studies have failed to demonstrate differences between RA and OA at the mRNA level of TLR2, TLR4 and TLR9 in synovial fibroblasts derived from joints, but in synovial tissues they observed weak expression of TLR2 mRNA in tissue sections of patients affected by OA compared with patients with RA [20]. Moreover, it was found that cultured synovial fibroblasts from patients with RA or OA express low levels of TLR2 and TLR9 mRNA, and no differences between RA and OA were found in this study [21]. In cultured RA and OA fibroblast-like synoviocytes (FLS), bacterial PGs and bacterial lipopeptide, but not CpG oligodeoxynucleotides, can activate, partially through TLR-2, cytokines and chemokines [21, 22]. Moreover, the expression of TLR2 was up-regulated by PGs but the expression of TLR9 was not up-regulated by CpG oligodeoxynucleotides in RA and OA FLS [17]. With regard to TLR4, data are scarce, but its involvement in the production of IFN-γ and the CXCl chemokine family in synovial cells has been reported [23].

Our previous studies suggest that proinflammatory cytokine and chemokine expression is down-regulated by VIP in RA fibroblasts. To examine whether modulation of TLR-mediated signalling is involved in the anti-inflammatory response to VIP of human RA cells, we studied the effects of VIP on TLR expression and signalling in RA synovial fibroblasts.

### Materials and methods

**Patients and tissue samples**

Synovial tissue was obtained from six patients with RA and four patients with OA at the time of surgery to replace a knee prosthesis. Informed consent was requested and obtained from every patient. All RA patients fulfilled the American College of Rheumatology 1997 criteria for the diagnosis of RA [24]. The study was performed according to the ethics recommendations of the Declaration of Helsinki and was approved by the Ethics Committee of the Hospital 12 de Octubre. FLS cultures were established from homogenized synovium in 10% fetal calf serum–Dulbecco’s Modified Eagle Medium (FCS-DMEM) [25]. FLS were used between passages 3 and 8. FLS were stimulated with 20 μg/ml LPS from *Salmonella enteritidis* (Sigma-Aldrich, Madrid, Spain) or with 10 nM TNF-α (Genzyme, Cambridge, UK) in the presence or absence of 10 nM VIP (Neosystem, Strasbourg, France) for 24 h. Culture supernatants were harvested for determination of chemokines by enzyme-linked immunosorbent assay (ELISA). RNA was also obtained from FLS cultures.

**Single-step quantitative real-time RT-PCR**

Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was performed with an ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). We used the SYBR® Green PCR Master Mix and RT-PCR kit in one-step RT-PCR, as suggested by the manufacturer (Applied Biosystems). Briefly, reactions were performed in 20 μl containing 50 ng of total RNA, 10 μl 2 × SYBR Green PCR Master Mix, 6.25U Multi-Scribe reverse transcriptase 10 μl RNase inhibitor and 0.1 μM of specific primers. The sequence of primers was: human β-actin sense, 5'-AGAAGGATCTTATGTGGGCG-3', antisense 5'-CATGGCTCCTCCGATTTGAC-3'; human TLR2, sense 5'-GGAAGAACATTCTCCTAATCAGGC-3', antisense 5'-CTTGGTACCCCTGAGGGA-3'; human TLR4, sense 5'-ATGGCATTTGGTCTTC-3', antisense 5'-CAGCAGCACTCGAGGA-3'; and human MyD88, sense 5'-CGGATGGTGGTGGTGTCTC-3', antisense 5'-CGCTTCTGATGGGCA CCT-3'. The GenBank accession numbers and numbers for the 5' and 3' ends of nucleotides for the PCR products are: β-actin, E00829, 1435–1535; TLR2, NM 003264, 207–307; TLR4, NM 138554, 112–212; and MyD88, NM 002468, 691–791. The amplification conditions were 30 min at 48°C, 10 min at 95°C, 40 cycles of denaturation at 95°C for 15 s, and annealing/extension at 60°C for 1 min.

For relative quantification, we calculated the n-fold differential expression by the ΔCt method (Ct, denoting the threshold cycle of PCR amplification at which product is first detected by fluorescence), which compares the amount of target gene amplification, normalized to the β-actin endogenous reference as previously described [26]. The correct size of the amplified products was checked by electrophoresis.

**Western blotting**

Proteins were extracted from FLS in ice-cold lysis buffer (10 mM Tris–HCl, pH 8, 1 mM ethylenediamine tetraacetate (EDTA), 150 mM NaCl, 0.1% sodium dodecyl sulphate (SDS), 10 μg/mL leupeptin, 10 μg/mL of aprotinin, 2 μg/mL of pepstatin A, and 0.5 mM phenylmethylsulphonyl fluoride). Protein extracts (50 μg) were subjected to 8% SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride (PVDF) membranes. Membranes were blocked with Tris-buffered saline (pH 7.6) containing 5% non-fat dry milk and 0.1% Tween-20 and then incubated overnight at 4°C with the following primary antibodies: rabbit anti-TLR4 (1:250; Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-MyD88 (1:6000; Alexis Biochemicals, Lausen, Switzerland), goat anti-TLR2 (1:400; Santa Cruz Biotechnology) and mouse anti-β-actin (1:10000; Sigma-Aldrich) as loading control. For detection, horseradish peroxidase conjugated secondary antibody at 1:5000 dilution was used. Proteins were detected using an enhanced chemiluminescence western blotting analysis system (Pierce, Rockford, IL, USA). Protein bands were analysed by densitometric analyses and normalized against the intensity of β-actin.

**ELISA**

The amounts of CCL2 (MCP-1) and CXCL8 (IL-8) in the supernatants of FLS cultures were determined with a human capture ELISA assay as previously described [9]. The intra-assay and inter-assay variability for chemokines determination was <5%.

**Statistical analysis**

Results are expressed as the mean ± s.e.m. The significance of the results was analysed using Student’s two tailed t-test. *P* values less than 0.05 were considered significant.

**Results**

**Expression of TLR4, TLR2 and MyD88 in RA and OA FLS**

We initially studied the constitutive expression of TLR2, TLR4 and MyD88 mRNA by quantitative real-time RT-PCR in FLS from patients with RA and OA. We found a 17-fold higher expression of TLR4 mRNA in RA compared with OA FLS (Fig. 1A). The mean expression of TLR2 mRNA was also significantly higher in RA FLS, being 8-fold higher than in OA FLS, whereas the expression of MyD88 mRNA was only
2.5-fold higher in RA FLS, not reaching statistical significance (Fig. 1B and C).

To analyse TLR2, TLR4 and MyD88 differences at the protein level, we performed western blot studies on FLS protein extracts. TLR2 was under the detection level in all FLS protein extracts, whereas it was readily detected in PBMC protein extracts used as positive control. A marked heterogeneity between individual FLS lines was observed for TLR4 and MyD88 protein expression. A 2-fold higher expression of TLR4 protein was observed in RA compared with OA FLS (Fig. 2). MyD88 protein levels were also heterogeneous in individual FLS lines, and although they were slightly higher in RA FLS the difference did not reach statistical significance (data not shown).

**Effect of VIP on TLR4 expression in FLS**

We next studied whether VIP modulates constitutive or induced TLR2, TLR4 and MyD88 expression in FLS cultures from patients with RA. By quantitative real-time PCR we observed that VIP does not modify the normalized expression of TLR2, TLR4 or MyD88 mRNA under basal, non-stimulated conditions in RA FLS (Fig. 3).

LPS and TNF-α induced a significant increase in TLR4 and MyD88 but not TLR2 mRNA expression in RA FLS. VIP significantly decreased LPS and TNF-α-induced TLR4 mRNA expression in RA FLS. VIP also significantly decreased LPS but not TNF-α-induced MyD88 expression in RA FLS.

LPS and TNF-α induction of TLR4 protein expression was also confirmed by western blot. Similar to what was observed at the mRNA level, treatment of RA FLS cultures with VIP blocked both LPS and TNF-α induction of TLR4 protein expression, whereas it did not have an effect on basal non-stimulated TLR4 protein levels (Fig. 4). In contrast, the smaller increase in MyD88 mRNA expression and its down-regulation by VIP were not confirmed at the protein level (data not shown).

**Effect of VIP on the production of chemokines**

To study whether the observed changes in TLR4 expression were accompanied by functional changes, we analysed the production of the chemokines CCL2 and CXCL8 in response to LPS stimulation. LPS induced a significant increase in CCL2 and CXCL8 release by RA FLS cultures (Fig. 5).

VIP decreased CXCL8 and CCL2 release by RA FLS cultures under non-stimulated conditions but the difference was statistically significant \( (P < 0.01) \) only for CCL2. In LPS-stimulated FLS from patients with RA, VIP significantly decreased CXCL8 and CCL2 release \( (P < 0.01 \) for CXCL8 and \( P < 0.001 \) for CCL2).

**Discussion**

Activation of the immune system through TLR is an emerging facet of the pathogenesis of human chronic inflammatory diseases such as RA [27]. Crosstalk between cytokines and TLR signalling pathways has been demonstrated in RA cells *in vitro*, and TLR can contribute to the induction of the synthesis of a large variety of proinflammatory mediators, such as cytokines, chemokines,
metalloproteinases and adhesion molecules [28]. TLR expression seems up-regulated in RA tissues and macrophages, and TLR are functional in synovial FLS. Although the mechanisms of expression and activation are not clear [20–22], several studies confirm that TLR expression is a cytokine-inducible feature [20, 28]. Our results confirm that the expression of TLR2 and MyD88 mRNA and that of TLR4 mRNA and protein are increased in cultured FLS from RA compared with OA patients, and that in the case of TLR4 it can be up-regulated in vitro by TNF-α and by its ligand LPS.

VIP has been shown to significantly reduce the incidence and severity of arthritis in an experimental model, completely abrogating joint swelling and destruction of cartilage and bone. The therapeutic effect of VIP was associated with down-regulation of both the inflammatory and the autoimmune component of the disease [4]. Recent studies suggest that VIP may represent an efficacious anti-arthritic treatment that modulates macrophage and T-cell cytokine profiles when used alongside a phosphodiesterase inhibitor [10]. Our previous studies in a murine model of inflammatory bowel disease induced by trinitrobenzene sulphonic acid suggest that VIP down-regulates TLR2 and TLR4 expression in parallel to a reduction in inflammatory and Th1-driven mediators and an improvement in the clinical and histopathological severity of the disease [29]. Our present data confirm that VIP directly interferes with TNF-α as well as with TLR4 signalling in FLS and that VIP is able to block downstream responses, such as chemokine expression and induced expression of TLR2, TLR4 and MyD88, through VIP receptors that have been described previously in FLS [30].

**FIG. 3.** Effect of VIP on mRNA expression for TLR4, TLR2 and MyD88. The mRNA expression of TLR4, TLR2 and MyD88 was studied by quantitative real-time PCR in FLS cultures from patients with RA under basal (non-stimulated) conditions and after stimulation with 20 μg/ml LPS or 10 nM TNF-α. The results were corrected for β-actin mRNA expression within each sample. Results are mean ± s.e.m. of two experiments performed in duplicate and include three FLS lines from different patients with RA. *P < 0.05, **P < 0.01.

**FIG. 4.** Effect of VIP on induced TLR4 expression. Western blot analysis of TLR4 protein expression in cultured FLS stimulated or not with (A) LPS or (B) TNF-α in the presence or absence of VIP at the indicated concentrations. An experiment representative of three is shown together with a densitometric analysis of TLR4 expression normalized to β-actin expression. *P < 0.05.
common intracellular pathways, in which NF-κB-induced TLR4 signalling [33]. TLR and cytokine receptors share
*includes three FLS lines from different patients with RA.
of three independent experiments performed in triplicate and
**effects of VIP signalling on NF-κB plays a pivotal role [34, 35]. Therefore, the well known negative
t蕃"is up-regulated in LPS- and TNF-α-treated RA FLS, and that VIP
**B activation may underlie
IP decreases TLR4 expression in RA FLS

To date, it is known that TLR signalling is mediated through four adapter molecules: MyD88, MAL/TIRAP, TRIF and TRAM. Moreover, MyD88 is the pivotal adapter protein, being essential for the production of the inflammatory network molecules [12, 13, 31]. In this regard, it has been reported that MyD88 is involved in the streptococcal model of arthritis [32]. Our present study demonstrates that mRNA expression of MyD88 is up-regulated in LPS- and TNF-α-treated RA FLS, and that VIP is able to significantly decrease its expression after LPS stimulation at the mRNA but not at the protein level. Further studies are needed to explain this discrepancy. Recently, it has been reported that TGF-β1 inhibits the MyD88-dependent pathway in LPS-induced TLR4 signalling [33]. TLR and cytokine receptors share common intracellular pathways, in which NF-κB activation plays a pivotal role [34, 35]. Therefore, the well known negative effects of VIP signalling on NF-κB activation may underlie the observed effects [36]. In this regard, we have reported in the collagen-induced arthritis model that in vivo VIP treatment prevents NF-κB nuclear translocation through the inhibition of IκBα phosphorylation and degradation [7].

Proliferative and angiogenic chemokines are important players in RA pathology and represent an important group of mediators that can be induced in RA FLS in response to cytokines and TLR ligands. TLR stimulation by PGN induces up-regulation of proinflammatory and angiogenic chemokines in RA FLS, and this stimulation increases the chemotactic activity of FLS for PBMC [22]. Our study demonstrates that RA FLS produce CXCL8 and CCL2 chemokines upon stimulation with the TLR4 ligand LPS. Although we have previously reported that TNF-α-stimulated FLS secrete chemokines [9], the present data argues for a direct activation via TLR4 since FLS are unable to produce TNF-α and other proinflammatory cytokines such as IFN-γ and IL-1α [37]. In addition, we show that VIP down-regulates proinflammatory chemokine production in response to TLR4 stimulation. Fibroblasts have been identified as a source of chemokines in synovial tissue of RA patients [38, 39], contributing to inflammation maintenance, and chemokine blockade had beneficial effects in animal models of RA [40, 41]. Our findings demonstrate that RA FLS activated via TLR4 produce chemokines which are down-regulated by VIP, supporting its potential to modulate chemokine-mediated joint inflammation.

In conclusion, these results confirm that there is differential expression of TLR4, TLR2 and MyD88 in RA FLS compared with OA ex vivo. In addition, VIP has a regulatory effect on TLR4 and MyD88 expression and function in FLS from RA and OA patients. Although further studies are needed to evaluate the mechanisms involved, our observation supports the hypothesis that VIP down-regulates multiple proinflammatory pathways, including TLR-mediated pathways, which extends its therapeutic actions from the murine model to human RA and provides new insights into its use in therapy.

![Figure 5](image)

**Figure 5.** Effect of VIP on CXCL8 and CCL2 production in cultured FLS. Supernatants of FLS cultures from RA patients in the basal condition and after stimulation with 20 μg/ml LPS were collected, and levels of (A) CXCL8 and (B) CCL2 were determined by sandwich ELISA. Each result is the mean ± S.E.M. of three independent experiments performed in triplicate and includes three FLS lines from different patients with RA. *P < 0.01; **P < 0.001.

Rheumatology

<table>
<thead>
<tr>
<th>Key messages</th>
</tr>
</thead>
<tbody>
<tr>
<td>• RA fibroblast-like synoviocytes display increased constitutive expression of TLR4, which is further up-regulated by LPS and TNF-α.</td>
</tr>
<tr>
<td>• The pleiotropic anti-inflammatory actions of VIP involve inhibitory effects on TLR4 expression and signalling.</td>
</tr>
</tbody>
</table>

Acknowledgements

This work was supported by grants G03/152 from the Fondo de Investigación Sanitaria (FIS), BFI 2002–03489 from Ministerio de Ciencia y Tecnologia, a postdoctoral fellowship from Junta de Comunidades de Castilla-La Mancha to I.G.-C. and a predoctoral fellowship from Ministerio de Ciencia y Tecnología to A.A. (Spain).

B.S., C.M., R.P.G. and J.L.P. have received a research grant from Genetrix SL, which holds a patent for the therapeutic use of VIP in RA.

References


